LDL-C levels should be lowered as much as possible to prevent cardiovascular disease, particularly in patients with high and very high risk, according to the 2019 ESC/EAS Guidelines for the management of dyslipidaemia. LDL-C goals have thus been lowered compared with the 2016 Guidelines.
Prof. Colin Baigent (chairperson of the guidelines task force) made it very clear that data take centre stage in the new ESC Guidelines on dyslipidaemia, alongside the categorisation of patients. “Refining the definition of risk was the first step we took, by distinguishing between very high-risk (>10% over 10 years) and high-risk (5-10% risk over 10 years) patients. The emphasis was on a large relative reduction in low-density lipoprotein cholesterol (LDL-C) to achieve a large absolute reduction where possible and to reduce the risk” .
“Lower is better in all available trials when it comes to LDL-C,” Prof. Baigent said. “There is now evidence that lowering LDL...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Fewer deaths and hospitalisations in HF patients with SGLT2-inhibitor dapagliflozin Next Article
Apixaban superior to VKAs for major bleeding, stroke/STE and all-cause mortality »
Table of Contents: ESC 2019
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.